NASDAQ · ADMAHealthcareBiotechnology

ADMA Biologics news

$9.96−1.58%
Close Sep 29, 2026 · split-adjusted
Articles · 30 days1English, de-duplicated
Positive00% of coverage
Neutral1100%
Negative00% of coverage

About ADMA Biologics

Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?
Zacks Investment ResearchSep 8, 9:30 AM ETNeutral

Despite a Buy-equivalent average brokerage recommendation (ABR of 2.00), the article advises caution. The Zacks Rank #3 (Hold) rating and unchanged consensus earnings estimate of $0.78 suggest the stock is expected to perform in line with the broader market rather than outperform, warranting a neutral stance.

ADMA DEADLINE TOMORROW: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMA
GlobeNewswire Inc.Aug 9, 11:41 AM ET▼ Negative

The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to artificially inflate revenue, and inadequate internal controls. These allegations indicate serious corporate governance and accounting issues that caused investor losses.

ADMA 3-DAY DEADLINE ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– Hagens Berman
GlobeNewswire Inc.Aug 7, 3:52 PM ET▼ Negative

The company is the subject of a securities fraud class action lawsuit alleging material misrepresentations about financial condition, revenue recognition, and undisclosed related-party transactions. A short-seller report exposed channel stuffing practices, resulting in a 31.6% stock price decline over two days, indicating severe loss of investor confidence and significant financial harm to shareholders.

MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ADMA
GlobeNewswire Inc.Aug 6, 11:51 AM ET▼ Negative

Company is subject to securities fraud allegations involving channel stuffing, undisclosed related party transactions, and inadequate internal controls. Stock experienced significant declines (16% and 13%) following negative reports and analyst downgrades, indicating loss of investor confidence.

Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
GlobeNewswire Inc.Aug 6, 9:35 AM ET▼ Negative

The company faces serious allegations of fraudulent business practices including channel stuffing, undisclosed related party transactions, and inadequate internal controls. These allegations resulted in a 29.1% stock price decline and triggered a securities fraud class action lawsuit, indicating significant investor harm and loss of confidence.

DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026
GlobeNewswire Inc.Aug 5, 10:39 PM ET▼ Negative

The company faces serious allegations of securities fraud including undisclosed related-party transactions, channel stuffing, and inadequate internal controls. Stock price collapsed 31.6% following revelations, with additional 13.9% decline after analyst downgrade, indicating severe loss of investor confidence and substantial shareholder value destruction.

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
GlobeNewswire Inc.Aug 4, 10:57 PM ET▼ Negative

The company is the subject of a securities class action lawsuit alleging material misstatements and omissions including undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations suggest serious corporate governance failures and potential fraud, resulting in investor losses.

ADMA 1-WEEK DEADLINE ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– HBSS
GlobeNewswire Inc.Aug 3, 5:38 PM ET▼ Negative

The company is accused of material financial misrepresentations, undisclosed related-party transactions, channel stuffing, and inadequate internal controls. Stock experienced severe declines (31.6% combined over two days, followed by additional 13.9% drop) following corrective disclosures, resulting in substantial shareholder losses and triggering a class action lawsuit.

ADMA BIOLOGICS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMA
GlobeNewswire Inc.Aug 3, 12:42 PM ET▼ Negative

The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations indicate serious corporate governance and accounting issues that resulted in investor losses.

ADMA DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 10 Deadline in Securities Class Action First Filed by the Firm – ADMA
GlobeNewswire Inc.Jul 31, 3:56 PM ET▼ Negative

The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. These allegations indicate serious corporate governance and accounting issues that resulted in investor losses.

AUGUST 10, 2026 INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
GlobeNewswire Inc.Jul 31, 6:55 AM ET▼ Negative

Company is facing securities fraud allegations involving channel stuffing, undisclosed related party transactions, and inadequate internal controls. Stock declined significantly (16% and 13%) following negative reports and analyst downgrades. The lawsuit alleges management made false and misleading statements about revenue growth.

ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA
GlobeNewswire Inc.Jul 30, 11:52 AM ET▼ Negative

The company is facing serious allegations of securities fraud including undisclosed related party transactions, channel stuffing to artificially inflate revenue, inadequate internal controls, and making materially false and misleading statements about its business operations. These are significant compliance violations that undermine investor confidence and indicate potential financial and operational misconduct.

ADMA BIOLOGICS DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
GlobeNewswire Inc.Jul 28, 3:37 PM ET▼ Negative

The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations indicate serious corporate governance and financial reporting violations that caused investor damages.

ADMA INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– HBSS
GlobeNewswire Inc.Jul 24, 1:58 PM ET▼ Negative

The company faces a securities fraud class action lawsuit alleging material misrepresentations about financial condition, revenue recognition, and undisclosed related-party transactions. A short-seller report exposed channel stuffing practices, resulting in a severe 31.6% stock price decline over two trading days and additional losses following a company response and analyst downgrade.

ADMA BIOLOGICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Urges ADMA Biologics, Inc. Stockholders to Contact the Firm Regarding Their Rights Before August 10th
GlobeNewswire Inc.Jul 23, 5:54 PM ET▼ Negative

The company faces serious allegations of fraudulent accounting practices including channel stuffing, undisclosed related party transactions, and inadequate internal controls. A short report triggered a 16.63% stock price decline, and a class action lawsuit has been filed against the company, indicating significant legal and financial risks.

ADMA Alert: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed
GlobeNewswire Inc.Jul 22, 7:33 PM ET▼ Negative

The company faces a securities fraud class action alleging material misrepresentations regarding financial condition, revenue recognition, and business practices. A short-seller report exposed alleged channel stuffing and undisclosed related-party transactions, resulting in a 31.6% stock price decline over two days and further losses following management's response and analyst downgrades.

INVESTOR DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead ADMA Investor Class Action Lawsuit – RGRD Law
GlobeNewswire Inc.Jul 20, 5:50 PM ET▼ Negative

The company faces serious allegations of financial fraud including channel stuffing, undisclosed related party transactions, and inadequate internal controls. Stock declined significantly (16% then 13%) following damaging reports, and a major analyst downgraded the stock from Overweight to Neutral, indicating loss of investor confidence.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
GlobeNewswire Inc.Jul 13, 7:21 PM ET▼ Negative

The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations indicate serious corporate governance and accounting issues that resulted in investor losses.

ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
GlobeNewswire Inc.Jul 10, 2:48 PM ET▼ Negative

The company is the subject of a securities class action lawsuit alleging material misstatements, undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls. These allegations suggest serious corporate governance and financial reporting issues that resulted in investor losses.

ADMA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
GlobeNewswire Inc.Jul 7, 4:50 PM ET▼ Negative

Company is facing securities fraud allegations involving channel stuffing, undisclosed related party transactions, and inadequate internal controls. Stock declined significantly (16% and 13%) following negative reports and analyst downgrades. The lawsuit alleges material misstatements about revenue growth.

ADMA CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
GlobeNewswire Inc.Jul 5, 11:50 AM ET▼ Negative

The company is accused of material securities fraud including channel stuffing, undisclosed related party transactions, and inadequate internal controls. The stock experienced a 29% decline following the investigative report, and the company faces significant legal liability and reputational damage from the class action lawsuit.

ADMA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of ADMA Biologics, Inc. Investors - Contact Kirby McInerney LLP by August 10, 2026
GlobeNewswire Inc.Jun 26, 7:30 PM ET▼ Negative

Company faces securities fraud allegations involving channel stuffing and undisclosed related party transactions. Stock price declined approximately 46% following short seller report exposure (from $13.59 to $8.29 over three days). Analyst downgrade from Cantor Fitzgerald and investor concerns about cash flow inconsistencies further support negative sentiment.

ADMA DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire Inc.Jun 24, 2:50 PM ET▼ Negative

The company faces serious allegations of securities fraud including undisclosed related party transactions, channel stuffing to inflate revenues, and inadequate internal controls. Stock price declined significantly (16% then 13%) following negative reports and analyst downgrades, indicating loss of investor confidence.

ADMA Biologics, Inc. Class Action Lawsuit Seeks Recovery for Investors; August 10, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
GlobeNewswire Inc.Jun 22, 6:30 PM ET▼ Negative

The company faces serious allegations of securities fraud including undisclosed related party transactions, channel stuffing to artificially inflate revenues, and inadequate internal controls. The stock experienced a significant 29.1% decline following the disclosure of these issues, indicating substantial investor losses and loss of confidence in the company's financial reporting.

ADMA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire Inc.Jun 19, 2:15 PM ET▼ Negative

The company faces serious allegations of financial fraud including channel stuffing, undisclosed related party transactions, and inadequate internal controls. Stock declined significantly (16% and 13%) following the short-seller report and analyst downgrade, indicating loss of investor confidence.

ADMA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ADMA Biologics, Inc. and Encourages Investors to Contact the Firm
GlobeNewswire Inc.Jun 17, 6:23 PM ET▼ Negative

The company faces serious allegations of fraudulent accounting practices including channel stuffing, undisclosed related party transactions, and inadequate internal controls. A short report triggered a 16.63% stock price decline, and a class action lawsuit has been filed against the company, indicating significant legal and reputational risks.

NASDAQ: ADMA: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against ADMA Biologics, Inc. (ADMA) – Contact Kessler Topaz Meltzer & Check, LLP
GlobeNewswire Inc.Jun 17, 11:00 AM ET▼ Negative

The company faces serious allegations of material misstatements, undisclosed related party transactions, channel stuffing to artificially inflate revenues, and inadequate internal controls. The stock experienced a significant 29.1% decline following exposure of these practices, indicating substantial investor losses and loss of confidence.

ADMA Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the ADMA Biologics, Inc. Class Action Lawsuit
GlobeNewswire Inc.Jun 15, 6:21 PM ET▼ Negative

The company faces serious allegations of misleading investors through undisclosed related party transactions, channel stuffing, and inadequate internal controls. The stock experienced significant declines (31.6% total over two days) following the exposure of these issues, indicating loss of investor confidence and potential material misstatements in financial reporting.

Deadline Approaching: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BenzingaJun 15, 1:38 PM ET▼ Negative

The company faces serious allegations of fraudulent accounting practices including channel stuffing and undisclosed related party transactions. The stock experienced a significant 29.1% decline following these revelations, and a class action lawsuit has been filed alleging materially false statements about business performance and inadequate internal controls.

Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action
BenzingaJun 12, 1:15 PM ET▼ Negative

The company faces serious allegations of securities fraud including channel stuffing, undisclosed related party transactions, and artificially inflated revenues. A class action lawsuit has been filed, and the stock experienced a significant 29.1% decline following the fraud allegations, indicating substantial investor losses and reputational damage.

Also mentions ADMA

Articles that tag ADMA but are mainly about other companies.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology